非随机对照试验比较低剂量阿司匹林和不使用阿司匹林的直肠癌放化疗的疗效。

Q2 Medicine
Medical Journal of the Islamic Republic of Iran Pub Date : 2025-03-20 eCollection Date: 2025-01-01 DOI:10.47176/mjiri.39.44
Kambiz Novin, Nafiseh Mortazavi, Pedram Fadavi
{"title":"非随机对照试验比较低剂量阿司匹林和不使用阿司匹林的直肠癌放化疗的疗效。","authors":"Kambiz Novin, Nafiseh Mortazavi, Pedram Fadavi","doi":"10.47176/mjiri.39.44","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer poses a significant global health challenge, with high incidence and mortality rates. Neoadjuvant chemoradiotherapy (CRT) is standard for rectal adenocarcinoma to improve surgical outcomes and reduce recurrence, yet the overall treatment efficacy remains inadequate. This study investigates the effects of low-dose aspirin as an adjunct therapy during neoadjuvant CRT in rectal cancer patients.</p><p><strong>Methods: </strong>This non-randomized controlled trial included 90 patients with histologically confirmed Stage II or III rectal adenocarcinoma, allocated into two arms (45 each) receiving standard neoadjuvant CRT with or without 100 mg of daily oral aspirin. Primary outcomes included pathological complete response (pCR) rates, while secondary outcomes encompassed tumor regression grade (TRG) and tumor down-staging. Safety was assessed by monitoring aspirin-related adverse events. Comparisons between groups for the primary outcome and secondary outcomes were performed using chi-square tests.</p><p><strong>Results: </strong>The aspirin group exhibited a significantly higher pCR rate of 26.6% compared to 17.7% in the control group (<i>P</i> < 0.001). Down-staging analysis indicated favorable outcomes in the aspirin compared to the control arm (47% vs. 24%, <i>P</i> < 0.001). No significant adverse events related to aspirin were reported.</p><p><strong>Conclusion: </strong>Low-dose aspirin enhances the efficacy of neoadjuvant chemoradiation in rectal cancer patients, leading to improved pCR and tumor down-staging with minimal toxicity. These findings support aspirin's potential as a cost-effective adjunct to standard treatment protocols, warranting further investigation in larger trials.</p>","PeriodicalId":18361,"journal":{"name":"Medical Journal of the Islamic Republic of Iran","volume":"39 ","pages":"44"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309339/pdf/","citationCount":"0","resultStr":"{\"title\":\"Non-Randomized Controlled Trial Comparing Response of Rectal Cancer Chemoradiation with and without Low-Dose Aspirin.\",\"authors\":\"Kambiz Novin, Nafiseh Mortazavi, Pedram Fadavi\",\"doi\":\"10.47176/mjiri.39.44\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Colorectal cancer poses a significant global health challenge, with high incidence and mortality rates. Neoadjuvant chemoradiotherapy (CRT) is standard for rectal adenocarcinoma to improve surgical outcomes and reduce recurrence, yet the overall treatment efficacy remains inadequate. This study investigates the effects of low-dose aspirin as an adjunct therapy during neoadjuvant CRT in rectal cancer patients.</p><p><strong>Methods: </strong>This non-randomized controlled trial included 90 patients with histologically confirmed Stage II or III rectal adenocarcinoma, allocated into two arms (45 each) receiving standard neoadjuvant CRT with or without 100 mg of daily oral aspirin. Primary outcomes included pathological complete response (pCR) rates, while secondary outcomes encompassed tumor regression grade (TRG) and tumor down-staging. Safety was assessed by monitoring aspirin-related adverse events. Comparisons between groups for the primary outcome and secondary outcomes were performed using chi-square tests.</p><p><strong>Results: </strong>The aspirin group exhibited a significantly higher pCR rate of 26.6% compared to 17.7% in the control group (<i>P</i> < 0.001). Down-staging analysis indicated favorable outcomes in the aspirin compared to the control arm (47% vs. 24%, <i>P</i> < 0.001). No significant adverse events related to aspirin were reported.</p><p><strong>Conclusion: </strong>Low-dose aspirin enhances the efficacy of neoadjuvant chemoradiation in rectal cancer patients, leading to improved pCR and tumor down-staging with minimal toxicity. These findings support aspirin's potential as a cost-effective adjunct to standard treatment protocols, warranting further investigation in larger trials.</p>\",\"PeriodicalId\":18361,\"journal\":{\"name\":\"Medical Journal of the Islamic Republic of Iran\",\"volume\":\"39 \",\"pages\":\"44\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309339/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Journal of the Islamic Republic of Iran\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47176/mjiri.39.44\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of the Islamic Republic of Iran","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47176/mjiri.39.44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:结直肠癌是全球健康面临的重大挑战,其发病率和死亡率都很高。新辅助放化疗(CRT)是直肠腺癌的标准治疗方法,可以改善手术效果,减少复发,但整体治疗效果仍然不足。本研究探讨小剂量阿司匹林作为直肠癌患者新辅助CRT辅助治疗的效果。方法:这项非随机对照试验包括90例组织学证实的II期或III期直肠腺癌患者,分为两组(每组45例),接受标准新辅助CRT治疗,每日口服阿司匹林100mg或不口服阿司匹林。主要结局包括病理完全缓解(pCR)率,而次要结局包括肿瘤消退等级(TRG)和肿瘤降期。通过监测阿司匹林相关不良事件来评估安全性。各组间主要结局和次要结局的比较采用卡方检验。结果:阿司匹林组的pCR率为26.6%,显著高于对照组的17.7% (P < 0.001)。降低分期分析显示,与对照组相比,阿司匹林组的预后较好(47%对24%,P < 0.001)。没有与阿司匹林相关的显著不良事件的报道。结论:小剂量阿司匹林可提高直肠癌患者新辅助放化疗的疗效,改善pCR,降低肿瘤分期,毒性最小。这些发现支持阿司匹林作为一种具有成本效益的辅助标准治疗方案的潜力,值得在更大规模的试验中进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Non-Randomized Controlled Trial Comparing Response of Rectal Cancer Chemoradiation with and without Low-Dose Aspirin.

Background: Colorectal cancer poses a significant global health challenge, with high incidence and mortality rates. Neoadjuvant chemoradiotherapy (CRT) is standard for rectal adenocarcinoma to improve surgical outcomes and reduce recurrence, yet the overall treatment efficacy remains inadequate. This study investigates the effects of low-dose aspirin as an adjunct therapy during neoadjuvant CRT in rectal cancer patients.

Methods: This non-randomized controlled trial included 90 patients with histologically confirmed Stage II or III rectal adenocarcinoma, allocated into two arms (45 each) receiving standard neoadjuvant CRT with or without 100 mg of daily oral aspirin. Primary outcomes included pathological complete response (pCR) rates, while secondary outcomes encompassed tumor regression grade (TRG) and tumor down-staging. Safety was assessed by monitoring aspirin-related adverse events. Comparisons between groups for the primary outcome and secondary outcomes were performed using chi-square tests.

Results: The aspirin group exhibited a significantly higher pCR rate of 26.6% compared to 17.7% in the control group (P < 0.001). Down-staging analysis indicated favorable outcomes in the aspirin compared to the control arm (47% vs. 24%, P < 0.001). No significant adverse events related to aspirin were reported.

Conclusion: Low-dose aspirin enhances the efficacy of neoadjuvant chemoradiation in rectal cancer patients, leading to improved pCR and tumor down-staging with minimal toxicity. These findings support aspirin's potential as a cost-effective adjunct to standard treatment protocols, warranting further investigation in larger trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
90
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信